Britt Drögemöller

 

---- Home | Research | Publications | Funding & Awards | Volunteer | Contact ----

 

PUBLICATIONS

 

Google Scholar Citations

 

  1. Drögemöller BI*, Monzon JG*, Bhavsar AP, Borrie AE, Brooks B, Wright GEB, Liu G, Renouf DJ, Kollmannsberger CK, Bedard PL, Aminkeng F, Amstutz U, Hildebrand CA, Gunaretnam EP, Critchley C, Chen Z, Brunham LR, Hayden MR, Ross CJD, Gelmon KA, Carleton BC. SLC16A5 genetic variation confers protection from cisplatin-induced ototoxicity in adult testicular cancer patients. JAMA Oncol. 2017 Apr 27. doi: 10.1001/jamaoncol.2017.0502. [Epub ahead of print]. *These authors contributed equally to this publication.

  2. Tarailo-Graovac M*, Drögemöller BI*, Wasserman WW, Ross CJD, van den Ouweland AMW, Darin N, Kollberg G, van Karnebeek CDM, Blomqvist M. Identification of a large intronic transposal insertion in SLC17A5 causing sialic acid storage disease. Orphanet J Rare Dis. 2017;12(1):28.  *These authors contributed equally to this publication

  3. hackseq Organizing Committee 2016. hackseq: Catalyzing collaboration between biological and computational scientists via hackathon. F1000Research 2017, 6:197.

  4. Ovenden ES, Drögemöller BI, van der Merwe L, Chiliza B, Asmal L, Emsley RA, Warnich L. Fine-mapping of antipsychotic response genome-wide association studies reveals novel regulatory mechanisms. Pharmacogenomics 2017;18(2):105-120.

  5. Anastasio N, Tarailo-Graovac M, Al-Khalifah R, Legault L, Drögemöller B, Ross CJ, Wasserman WW, van Karnebeek C, Buhas D. Mitochondrial Complex III Deficiency with Ketoacidosis and Hyperglycemia Mimicking Neonatal Diabetes. JIMD Rep. 2017;31:57-62.

  6. Lee JJY, van Karnebeek CDM, Drögemoller B, Shyr C, Tarailo-Graovac M, Eydoux P, Ross CJ, Wasserman WW, Björnson B, Wu JK. Further validation of the SIGMAR1 c.151+1G>T mutation as cause of distal hereditary motor neuropathy. Child Neurology Open 2016;3:1-5.

  7. Tarailo-Graovac M, Shyr C, Ross CJ, Horvath GA, Salvarinova R, Ye XC, Zhang L-H, Bhavsar APB, Lee JJY, Drögemöller BI, Abdelsayed M, Alfadhel M, Armstrong L, Baumgartner MR, Burda P, Connolly MB, Cameron J, Demos M, Dewan T, Dionne J, Evans AM, Friedman JM, Garber I, Lewis S, Ling J, Mandal R, Mattman A, McKinnon M, Michoulas A, Metzger D, Ogunbayo OA, Rakic B, Rozmus J, Ruben P, Sayson B, Santra S, Schultz KR, Selby K, Shekel P, Sirrs S, Skrypnyk C, Superti-Furga A, Turvey SE, Van Allen MI, Wishart D, Wu J, Wu J, Zafeiriou D, Kluijtmans L, Wevers RA, Eydoux P, Lehman AM, Vallance H, Stockler-Ipsiroglu S, Sinclair G, Wasserman WW, van Karnebeek CD. Exome Sequencing and the Management of Neurometabolic Disorders. N Engl J Med. 2016;374(23):2246-55.

  8. Langlois S, Tarailo-Graovac M, Sayson B, Drögemöller B, Ross C, Swenerton A, van Karnebeek CDM. De novodominant mutations affecting the motor domain of KIF1A are a cause of PEHO syndrome. Eur J Hum Genet. 2016;24(6):949-53.

  9. Santra S, Cameron JM, Shyr C, Zhang L, Drögemöller B, Ross CJ, Wasserman WW, Wevers RA, Rodenburg RJ, Gupte G, Preece MA, van Karnebeek CD. Cytosolic phosphoenolpyruvate carboxykinase deficiency presenting with acute liver failure following gastroenteritis. Mol Genet Metab. 2016;118(1):21-7.

  10. Röhrich C*, Drögemöller B*, Ikediobi O, van der Merwe L, Grobbelaar N, Wright G, McGregor N, Warnich L. CYP2B6*6 and CYP2B6*18 predict long-term efavirenz exposure measured in hair samples in HIV-positive South African women. AIDS Res Hum Retroviruses. 2016;32(6):529-38. *These authors contributed equally to this publication.

  11. Drögemöller B, Emsley R, Chiliza B, van der Merwe L, Wright G, Daya M, Hoal E, Malhotra A, Lencz T, Robinson D, Zhang J, Asmal L, Niehaus D, Warnich L. The identification of novel genetic variants associated with antipsychotic treatment response outcomes in first episode schizophrenia patients. Pharmacogenet Genomics. 2016;26(5):235-42.

  12. Dodgen T, Drögemöller B, Wright G, Warnich L, Steffens F, Cromarty D, Alessandrini M, Pepper M. Evaluation of predictive CYP2C19 genotyping assays relative to measured phenotype in a demographic South African population. Pharmacogenomics. 2015;16(12):1343-54.

  13. Drögemöller B, Niehaus D, Chiliza B, van der Merwe L, Asmal L, Malhotra A, Wright G, Emsley R, Warnich L. Patterns of variation influencing antipsychotic treatment outcomes in South African first episode schizophrenia patients. Pharmacogenomics. 2014;15(2):189-99.

  14. Drögemöller B, Wright G, Warnich L. Considerations for rare variants in drug metabolism genes and the clinical implications. Expert Opin Drug Metab Toxicol. 2014;10(6):873-84.

  15. Drögemöller B, Wright G, Niehaus D, Emsley R, Warnich L. Next generation sequencing of pharmacogenes: a critical analysis focusing on schizophrenia treatment. Pharmacogenet Genomics. 2013;23(12):666-74.

  16. Drögemöller B*, Plummer M*, Korkie L*, Agenbag G, Dunaiski A, Niehaus D, Koen L, Gebhardt S, Schneider N, Olckers A, Wright G, Warnich L. Characterization of the genetic variation present in CYP3A4 in three South African populations. Front Gene. 2013;4:17. *These authors contributed equally to this publication.

  17. Dodgen T, Hochfeld W, Fickl H, Asfaha S, Durandt C, Rheeder P, Drögemöller B, Wright G, Warnich L, Labuschagne D de J, van Schalkwyk A, Gaedigk A, Pepper M. Introduction of the AmpliChip CYP450 Test to a South African cohort: a platform comparative prospective cohort study. BMC Med Genet. 2013;14:20.

  18. Wright G, Niehaus D, van der Merwe L, Koen L, Korkie L, Kinnear C, Drögemöller B, Warnich L. Association of MB-COMT polymorphisms with schizophrenia-susceptibility and symptom severity in an African cohort. Prog Neuropsychopharmacol Biol Psychiatry. 2012;39:163-9.

  19. van Tuyll van Serooskerken A*, Drögemöller B*, Te Velde K, Bladergroen R, Steijlen P, Poblete-Gutiérrez P, van Geel M, van Heerden C, Warnich L, Frank J. Extended haplotype studies in South African and Dutch variegate porphyria families carrying the recurrent p.R59W mutation confirm a common ancestryBr J Dermatol.2012;166:261-5. *These authors contributed equally to this publication.

  20. Drögemöller B, Wright G, Niehaus D, Emsley R, Warnich L. Whole genome resequencing in pharmacogenomics: moving away from past disparities to globally representative applications. Pharmacogenomics. 2011;12:1717-28.

  21. Warnich L, Drögemöller B, Pepper M, Dandara C, Wright G. Pharmacogenomic research in South Africa: lessons learned and future opportunities in the rainbow nation. Curr Pharmacogenomics Person Med.  2011;9:191-207. 

  22. Wright G, Niehaus D, Koen L, Drögemöller B, Warnich L. Psychiatric genetics in South Africa: cutting a rough diamond. Afr J Psychiatry (Johannesbg). 2011;14:355-66.

  23. Drögemöller B, Wright G, Niehaus D, Koen L, Malan S, Da Silva D, Hillermann-Rebello R, La Grange A, Venter M, Warnich L. Characterization of the genetic profileof CYP2C19 in two South African populations. Pharmacogenomics. 2010;11:1095–103.

  24. Wright G, Niehaus D, Drögemöller B, Koen L, Warnich L. Elucidation of CYP2D6 genetic diversity in a unique African population: implications for the future application of pharmacogenetics in the Xhosa population. Ann Hum Genet. 2010;74:340-50.